Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma
Sarah A. Thurman(Beth Israel Deaconess Medical Center), Abram Recht(Beth Israel Deaconess Medical Center), Barbara Silver(Brigham and Women's Hospital), Stuart J. Schnitt(Brigham and Women's Hospital), Rebecca Gelman(Dana-Farber Cancer Institute), Jay R. Harris(Harvard University), James L. Connolly(Beth Israel Deaconess Medical Center)
International Journal of Radiation Oncology*Biology*Physics
April 18, 2004
Cited by 56
Related Papers
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
Molecular characterization of the tumor microenvironment in breast cancer
|Cancer Cell|2004|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Prognostic Factors in Breast Cancer
|Archives of Pathology & Laboratory Medicine|2000|1.1k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k